REFRIGERATOR PRESENTATION AVAILABLE FOR THE 2026–2027 FORMULATION

mNEXSPIKE®
COVID-19 Vaccine, mRNA

Vaccine Operations Guide

mNEXSPIKE (2026–2027 Formula) Is Available Exclusively as a Pre-filled Syringe and Is Stored Refrigerated[1]

Store refrigerated between 36 °F to 46 °F (2 °C to 8 °C)*

DO NOT FREEZE

After removal from refrigerated conditions, mNEXSPIKE can be **stored up to 12 hours** between 46 °F to 77 °F (8 °C to 25 °C)*

Preparation for Administration

- With tip cap upright, remove tip cap by twisting counterclockwise until tip cap releases. Remove tip cap in a slow, steady motion. Avoid pulling tip cap while twisting
- Attach the needle by twisting in a clockwise direction until the needle fits securely on the syringe
- Immunizer should select a needle of appropriate size and gauge for intramuscular injection
- Discard after single use

*During storage, minimize exposure to room light, and avoid exposure to direct sunlight and ultraviolet light. Do not use after the expiration date shown on the label.[1]

Dosing and Administration[1]

For intramuscular injection only.

Indication	Dose and Schedule
Individuals ≥65 years of age	**0.2 mL, single dose** If previously vaccinated, administer ≥3 months after the last dose of COVID-19 vaccine
Individuals 12–64 years of age with ≥1 underlying condition that puts them at high risk for severe outcomes from COVID-19	**0.2 mL, single dose** If previously vaccinated, administer ≥3 months after the last dose of COVID-19 vaccine

Product Identification, Diagnosis, and Procedural Codes[1–4]

Type	Code	Description
NDC	80777-401-60 (10-digit) 80777-0401-60 (11-digit)	Carton of 10 pre-filled syringes
	80777-401-17 (10-digit) 80777-0401-17 (11-digit)	Single-dose pre-filled syringe
CVX	334	SARS-CoV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 10 mcg/0.2 mL dose
MVX	MOD	Moderna
CPT®†	91323	**Vaccine Product Code** Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 10 mcg/0.2 mL dosage, for intramuscular use vaccine
	90480	**Vaccine Administration Code** Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, single dose
ICD-10-CM	Z23	Encounter for immunization

†CPT is a registered trademark of the American Medical Association (AMA).

AMA, American Medical Association; COVID-19, coronavirus disease 2019; CPT, Current Procedural Terminology; CVX, vaccine administered; ICD-10-CM, International Classification of Diseases, Tenth Revision, Clinical Modification; LNP, lipid nanoparticle; mRNA, messenger RNA; MVX, Manufacturer of Vaccine; NDC, National Drug Code.

References: 1. mNEXSPIKE Prescribing Information. Moderna; 2026. **2.** CDC. Accessed July 27, 2026. https://www.cdc.gov/iis/code-sets/fall-season-respiratory-codes.html **3.** CMS. Accessed July 27, 2026. https://www.cms.gov/medicare/payment/covid-19/coding-covid-19-vaccine-shots **4.** ICD10Data.com. 2026 ICD-10-CM Diagnosis code Z23. Accessed July 27, 2026. https://www.icd10data.com/ICD10CM/Codes/Z00-Z99/Z20-Z29/Z23-/Z23

mNEXSPIKE is a trademark of Moderna.
© 2026 Moderna US-COV-2500143 08/2026

INDICATION

mNEXSPIKE® (COVID-19 Vaccine, mRNA) is a vaccine indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

mNEXSPIKE is approved for use in individuals who are:

- 65 years of age and older, or
- 12 years through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.

IMPORTANT SAFETY INFORMATION

Contraindications

Do not administer mNEXSPIKE® to individuals with a known history of severe allergic reaction (e.g., anaphylaxis) to any component of mNEXSPIKE or to individuals who had a severe allergic reaction following a previous dose of SPIKEVAX (COVID-19 Vaccine, mRNA) or any Moderna COVID-19 vaccine authorized for emergency use.

Warnings and Precautions

- **Management of Acute Allergic Reactions:** Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of mNEXSPIKE.
- **Myocarditis and Pericarditis:** Postmarketing data with authorized or approved mRNA COVID-19 vaccines have demonstrated increased risks of myocarditis and pericarditis, with onset of symptoms typically in the first week following vaccination. The observed risk has been highest in males 12 years through 24 years of age.
- **Syncope (fainting):** May occur in association with administration of injectable vaccines. Procedures should be in place to avoid injury from fainting.
- **Altered Immunocompetence:** Immunocompromised persons, including individuals receiving immunosuppressive therapy, may have a diminished immune response to mNEXSPIKE.
- **Limitations of Vaccine Effectiveness:** mNEXSPIKE may not protect all vaccine recipients.

Adverse Reactions

The most commonly reported (≥10%) adverse reactions were pain at the injection site, fatigue, headache, myalgia, chills, arthralgia, axillary swelling or tenderness, and nausea/vomiting.

Reporting Adverse Events and Vaccine Administration Errors

The vaccination provider is responsible for mandatory reporting of certain adverse events to the Vaccine Adverse Event Reporting System (VAERS) online at https://vaers.hhs.gov or by calling 1-800-822-7967.

For Colorado and Connecticut price disclosure, please visit https://modernadirect.com/wac-disclosure.

Please scan the QR code or ask your representative for Full Prescribing Information.

moderna